Curie.Bio: Empowering Biotech Founders With a Revolutionary VC Model
With nearly $1 billion raised, Curie.Bio provides immediate access to a team of elite drug hunters, operators, and R&D services, ensuring founders can focus on breakthroughs rather than building infrastructure.
The firm's unique offering includes unparalleled support through shared services, co-piloting, and founder-focused resources. Curie’s 80-person team of biotech veterans works hand-in-hand with portfolio companies, leveraging their collective experience in developing over 150 clinical-stage drugs and 30+ approved products. Founders receive expert guidance on drug target selection, milestone planning, competitor analysis, and experimental design. Curie.Bio invests in a diverse portfolio of early-stage therapeutics companies with blockbuster potential, supporting both platform-based and asset-centric models.
George Voren, PhD – VP, Founder Strategy and Operations at Curie.Bio
George combines deep expertise in academia, biotech, and venture capital to help founders transform innovative scientific concepts into impactful medicines. With a Neuroscience PhD from The Scripps Research Institute, George contributed to the discovery of AZD4041, now in Phase 2 trials, by collaborating with CROs and AstraZeneca. At Flagship Pioneering, George played dual roles as a founder and investor, helping transform early-stage concepts into funded companies like Vesalius Therapeutics. His time at Relay Therapeutics deepened his expertise in small molecule drug discovery, guiding genetic disease programs from target selection to execution. At Curie.Bio, George ensures biotech founders have access to top-tier expertise, tools, and services to succeed.
This webinar will be hosted by SPARK Norway.
Online via MS Teams | Please register here!
Registration to the webinar is required in advance. Please register no later than 19th January 2025. Please note that you will receive the Zoom link and access code the evening before the lecture and that access to last minute registrations, cannot be guaranteed.
SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Poland, SPARK Tel Aviv, SPARK Denmark, SPARK Zürich and SPARK at the Faculty of Medicine, Masaryk University. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in the life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.
